Get to know our clinical trials
Trial of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma (HCC) who have progressed after first-line therapy containing immune checkpoint inhibitors.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- RANDOMIZED PHASE 2 STUDY TO EVALUATE THE OPTIMIZED DOSE, SAFETY AND EFFICACY OF LIVMONIPLIMAB IN COMBINATION WITH BUDIGALIMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE PROGRESSED AFTER FIRST-LINE THERAPY CONTAINING IMMUNE CHECKPOINT INHIBITORS. IMMUNOTHERAPY
- Code EudraCT: 2022-502948-13
- Protocol number: M24-147
- Promoter: Abbvie farmacéutica
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.